Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2017

View Archived Issues

Lysogene's candidate for GM1 gangliosidosis wins FDA rare pediatric disease designation

Telix signs product collaboration and purchase option agreement with Atlab

FDA accepts Ezra's NDA for EZR-104 to treat hypertension and heart failure

Full phase I data reported for novel anti-HIV compound ABX-464

Novo Nordisk initiates first human dose trial of NNC0194-0499

FDA approves Imbruvica for marginal zone lymphoma

Symbiomix Therapeutics submits NDA for Solosec

AbCellera receives grant to discover monoclonal antibodies against Mtb

PhaseBio obtains financing to support study of PB-1046

hERG as a novel glioblastoma survival marker

Cytori to acquire Azaya Therapeutics assets

Discovery of new chemical probe for BRPF proteins for cellular and in vivo studies

EUROSTARS funding to support development of LiPlaCis

FDA approves Rhofade, Allergan's topical treatment for persistent facial erythema

The University of Texas patents novel GLS inhibitors

TP Therapeutics presents new protein kinase inhibitors

FDA acknowledges receipt of NDA for Shire's ADHD drug SHP-465

Lilly identifies novel MetAP2 and DPP IV inhibitors

Cynata and FUJIFILM sign license option agreement

Roche divulges novel DDR1 inhibitors

PharmAthene, Altimmune enter merger agreement

Jilin University and Shanghai Pharmaceuticals Holding identify new JAK inhibitors

FDA approves Trulance for chronic idiopathic constipation

UCB submits sNDA for Briviact in U.S.

EMA awards orphan designation to Abeona Therapeutics' ABO-101

Japanese priority review for regorafenib in second-line treatment of unresectable HCC

Merrimack Pharmaceuticals -- refocused for 2017

Suliqua approved in Europe for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
ATNM-400 radioconjugate shows efficacy in resistant breast cancer
BioWorld Science
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies...